Richmond Pharmacology host ground breaking Early Phase Trials Integration seminar at the Royal Society of Medicine

Posted:
22
December 2005

Richmond Pharmacology host ground breaking Early Phase Trials Integration seminar at the Royal Society of MedicineThe Early Phase Trials Integration seminar held recently at the Royal Society of Medicine was seen as a huge success by all who attended.The seminar generated valuable discussions between guest speakers and the Pharmaceutical industry, and explored innovative new ways to maximize the efficiency and speed of Early Phase research.The seminar focused on the developments around EU Legislations which have re-defined the boundaries of Phase I and opened a new era of opportunity to expedite compounds through the Early Phases.World leading expert speakers from St George's University London, Mayday University Hospital & NHS trust and the ABPI outlined the new context within which clinical trials are conducted. Presentations on innovative new methodology were reviewed to identify how a CRO like Richmond Pharmacology can add value to pharmacology and patient studies.Pharmacology and patient studies can now be integrated or work independently of one another. Clinical & therapeutic innovations enable Early Phase research to deliver more dynamic and insightful studies, maximizing the probability of a compound reaching the later Phases.This new era of Early Phase research demands 3 foundations which were explored during the day:

  1. Commercial in- and out-patient facilities
  2. Acute NHS environment
  3. Therapeutic expertise

Delegate feedback has been positive. Everyone who attended benefited from the highly informative and educational day which was also accredited by the Faculty of Pharmaceutical Medicine (FPM).View presentations from the seminar

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more